FDA Recalls Over 13,000 Bottles of Chlorthalidone Tablets Due to Quality Issues

MIA — September 29, 2026

The U.S. Food and Drug Administration (FDA) has issued a recall for over 13,000 bottles of chlorthalidone tablets, a medication widely prescribed for managing high blood pressure. This recall was prompted by quality issues that could potentially compromise patient safety.

The recall was officially announced on September 29, 2026, following an investigation that revealed the affected batches did not meet the FDA’s stringent quality standards. The chlorthalidone tablets in question were manufactured by Inventia Healthcare, a pharmaceutical company based in India. The specific lot numbers involved in the recall have been identified, and healthcare providers are being urged to check their inventories.

Chlorthalidone is a thiazide diuretic that helps to lower blood pressure and reduce the risk of heart disease. It is commonly prescribed to patients with hypertension and is often used in combination with other medications. The recall affects a significant number of bottles—13,200 in total—raising concerns about the potential impact on patients who rely on this medication for their health.

The trigger for this recall was a quality control issue identified during routine inspections, which highlighted that some tablets may not contain the correct dosage of the active ingredient. This discrepancy poses a serious risk, as patients may not receive the intended therapeutic effect, leading to uncontrolled hypertension and associated health risks.

This development is receiving heightened attention due to the critical nature of blood pressure management in public health. High blood pressure is a leading risk factor for cardiovascular diseases, and any disruption in medication supply can have serious implications for patient care. The FDA has emphasized the importance of patient safety and the need for immediate action to prevent any adverse health outcomes.

Locally, this recall could affect thousands of patients in Miami and across the United States, particularly those who are dependent on chlorthalidone for their hypertension management. Nationally, it underscores the ongoing challenges in pharmaceutical manufacturing and quality assurance, raising questions about regulatory oversight and the safety of imported medications.

Looking ahead, healthcare providers are advised to contact patients who may have received the recalled medication and to provide alternative treatment options. The FDA is also expected to conduct further investigations into the manufacturing practices of Inventia Healthcare to ensure compliance with safety standards. Patients are encouraged to report any adverse effects or concerns to their healthcare providers and the FDA.

This recall serves as a reminder of the critical importance of quality control in pharmaceuticals and the need for vigilance in monitoring the safety of medications that millions rely on daily.

Source: nbcdfw.com